Investor Relations. News · Presentations · Stock Information · Analyst Coverage · SEC Filings · Corporate Governance · Annual Meeting and Proxy materials ...
Investor Relations. News · Presentations · Stock Information · Analyst Coverage · SEC Filings · Corporate Governance · Annual Meeting and Proxy materials ...
CHARLOTTESVILLE, Va., November 14, 2022—Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion ... investor relations section of Diffusion's website, investors ...
Investor Contacts: David Kalergis, CEO. Diffusion Pharmaceuticals Inc. (434) 220-0718. dkalergis@diffusionpharma.com. LHA Investor Relations. Kim Sutton ...
People also ask
Is Diffusion Pharmaceuticals a good buy?
Who is the board of directors of diffusion pharmaceuticals?
Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body's ability to deliver oxygen to the ...
Missing: investor relations
Requests for those documents should be directed to Investor Relations Department, Diffusion Pharmaceuticals Inc., 2020 Avon Court, Suite 4, Charlottesville,.
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
Dec 5, 2022 · The full text of the letter follows. December 5, 2022. Dear Fellow Stockholder,. The value of your investment is at stake at Diffusion's 2022 ...
Check out our DFFN stock analysis, current DFFN quote, charts, and historical prices for Diffusion Pharmaceuticals Inc stock.
... Diffusion Investor Relations by e-mailing info@diffusionpharma.com. ... DFFN”. However, our common stock would receive a new CUSIP number. Increase the Per Share ...